Eli Lilly Lowers Zepbound List Price

This is a Zepbound news story, published by CNBC, that relates primarily to Zepbound news.

Zepbound news

For more Zepbound news, you can click here:

more Zepbound news

Zepbound news

For more Zepbound news, you can click here:

more Zepbound news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

weight loss drug Zepbound

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Zepbound Eli Lilly news, milligram dose news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Zepbound doses

CNBC

•

Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply

Summary

Nutrition label

79% Informative

Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price.

The move aims to increase access for patients without insurance coverage for the highly popular injection.

The company is now offering 2.5 -milligram and 5 milligram single-dose vials for $ 399 per month and $ 549 per month through its direct-to-consumer website.

Patients with a valid prescription can purchase vials from a new "self-pay pharmacy" section on the site, LillyDirect .

All doses of Zepbound are now listed as available on the FDA 's drug shortage database.

Thousands of online platforms offering compounded versions of weight loss drugs from Novo Nordisk and Eli Lilly have cropped up.

"We believe that the U.S. population is actually a target for untested, unapproved, unregulated anti-obesity medications," Jonsson says.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity